LTR Pharma has today announced that SPONTAN® has been prescribed to the first patients under the TGA’s Special Access Scheme (SAS).
Patients were prescribed by the Restorative Sexual Health Clinic (RSHC), which provides evidence-based care to help individuals achieve optimal sexual function and improve intimate relationships.
Restorative Sexual Health Clinic’s founder, Melissa Hadley Barrett, said,
“We see SPONTAN as a valuable addition to our therapeutic capability. SPONTAN complements our holistic approach, offering our patients an innovative option to help address their sexual health concerns and enhance overall well-being.”
This marks a significant milestone for the Company, as the world’s first prescription of a PDE5 (Viagra, etc) nasal spray.
LTR Pharma Chairman, Lee Rodne said:
“The use of SPONTAN under the early access program marks a watershed moment for LTR Pharma. It demonstrates both the urgent need for fast-acting ED medication and SPONTAN’s potential to address a high unmet need for a fast and on-demand ED treatment and allows for hands-on, real-world experience with SPONTAN.”